Measurements of IL-6, soluble IL-6 receptor and soluble gp130 in sera of B-cell lymphoma patients. Does viscum album treatment affect these parameters?
Interleukin-6 (IL-6) can be involved in several diseases including lymphoid malignancies. This cytokine binds to soluble IL-6 receptor (sIL-6R) circulating in blood, leading to signal transduction via gp130. Soluble IL-6R shows agonistic activity for IL-6, and the soluble form of gp130 (sgp130) an antagonistic effect against the complex IL-6/sIL-6R. Viscum album extract (Iscador) as an immunomodulator is used in the treatment of malignant disorders. In this study we investigated the effect of this treatment on the serum levels of IL-6, sIL-6R and sgp130 in B-cell lymphoma patients (n = 27), in comparison to healthy controls (n = 28). Twenty-one of 27 patients had been treated previously with chemo/radiotherapy. The patients were divided into two groups; those with short-term (investigated before and during treatment) or those with long-term Viscum album (VA) therapy (investigated during therapy). The serum levels of the three parameters were determined by ELISA. In patients having short-term treatment IL-6 values were similar to those of controls. During long-term therapy the values were significantly lower (P<0.05). The values of sIL-6R were elevated only in long-term treated patients (P<0.05), the values of sgp130 in both short-term (P<0.05) and in long-term treated patients (P=0.001). There is a significant correlation (P<0.05) between levels of sIL-6R and sgp130 in both therapy groups at 24 hours after injection. This indicates that the potent effect of sIL-6R on the biological activity of IL-6 could be inhibited by sgp130 as antagonist. Clinical data show that half of the patients (6/12) with long-term treatment had a continuous complete remission, whereas only 2/15 patients with short-term treatment had a complete remission.
Kovacs
E
E
Society of Cancer Research, Kirschweg, Arlesheim, Switzerland. evakovacsbenke@hotmail.com
Kuehn
J J
JJ
D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000097:blood* / Q000378:metabolism; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D050822:Cytokine Receptor gp130; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D015850:Interleukin-6 / Q000097:blood* / Q000378:metabolism; D016393:Lymphoma, B-Cell / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood* / Q000378:metabolism; D008875:Middle Aged; D010936:Plant Extracts / Q000008:administration & dosage / Q000627:therapeutic use*; D010940:Plant Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D019947:Receptors, Interleukin-6 / Q000097:blood* / Q000378:metabolism; D012074:Remission Induction; D012995:Solubility
D015703:Antigens, CD; D000972:Antineoplastic Agents, Phytogenic; C494199:IL6ST protein, human; D015850:Interleukin-6; D008562:Membrane Glycoproteins; D010936:Plant Extracts; D010940:Plant Proteins; D019947:Receptors, Interleukin-6; D050822:Cytokine Receptor gp130; C077177:viscum album peptide